Therapy Areas: AIDS & HIV
Malaysia's drugs regulator approves Sinovac's COVID-19 vaccine for 12-17 year olds
1 October 2021 -

Malaysia's drug regulator has given conditional approval for Chinese biopharmaceutical company Sinovac Biotech's (Nasdaq:SVA) COVID-19 vaccine to be used in young people aged between 12 and 17, Reuters news agency reported on Friday.

The health ministry stated that the drugs regulator had advised priority for Sinovac's vaccine among teenagers without co-morbidities or allergy problems, or otherwise deemed unsuitable for the Pfizer (NYSE:PFE)/BioNTech (Nasdaq:BNTX) vaccine.

Reportedly, teenagers younger than 18 in Malaysia started receiving COVID-19 doses last month, after vaccinations of more than 80% of adults were completed.

Login
Username:

Password:


Related Headlines

Applied BioCode Launches 28 New Fungal Analyte Specific Reagents in the US

US NIH and Moderna in dispute over patent claim for COVID-19 vaccine

Regeneron announces single dose of REGEN-COV provides long-term protection against COVID-19 in Phase 3 trial

KalVista Pharmaceuticals Presents Data Demonstrating KVD900 Achieves Rapid Exposure and Improves Outcomes as Oral On-Demand Treatment of HAE

Astria Therapeutics Presents New Preclinical Data Showing the Differentiated Profile of STAR-0215, in Development to Treat Hereditary Angioedema

Lilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the US government for the Treatment or Post-Exposure Prevention of COVID-19

Adaptive Phage Therapeutics Inks Agreement with ARLG to Support Phase 1b/2 Cystic Fibrosis Study

Venatorx Pharmaceuticals Forges Collaboration with Roche to Develop New Class of Antibiotics targeting WHO Critical Priority Pathogen

Axial Therapeutics Receives FDA Clearance of IND Application and Initiates Phase 2b Trial for AB-2004, Lead Gut-Targeted, Molecular Therapeutic for the Treatment of Irritability in Autism Spectrum Disorder

Axial Therapeutics Receives FDA Clearance of IND Application and Initiates Phase 2b Trial for AB-2004, Lead Gut-Targeted, Molecular Therapeutic for the Treatment of Irritability in Autism Spectrum Disorder

Axial Therapeutics Receives FDA Clearance of IND Application and Initiates Phase 2b Trial for AB-2004, Lead Gut-Targeted, Molecular Therapeutic for the Treatment of Irritability in Autism Spectrum Disorder

US likely to make available COVID-19 vaccines for children between five to 11 in November 2021

US President's chief medical adviser says US can prevent another COVID-19 surge with higher vaccination rates

The IMA Group strengthens and broadens clinical research offerings via acquisition of DXRG

US FDA Approves Ocular Therapeutix Supplemental New Drug Application for Dextenza 0.4 mg for Intracanalicular Use for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis